Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place ...

SANTA CLARA, Calif., September 03, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP ...

Agilent Technologies Inc. (NYSE: A) today announced its participation as a premium sponsor at the upcoming European Congress of Pathology (ECP) 2025, taking place in Vienna, Austria, from September ...

SANTA CLARA, Calif., September 02, 2025--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that its MMR IHC Panel pharmDx (Dako Omnis) has received class C companion diagnostic (CDx ...

The Dako Omnis test identifies mismatch repair deficiencies in colorectal cancer, aiding in treatment decisions and potentially improving patient outcomes. Hernexeos, a kinase inhibitor, offers a new ...

NEW YORK – Agilent Technologies said Tuesday that it has received certification under the EU's In Vitro Diagnostic Regulation (IVDR) for a companion diagnostic test that is used to inform the ...

Agilent Technologies Inc (NYSE:A) presented its third-quarter fiscal year 2025 financial results on August 27, 2025, showcasing stronger-than-expected performance and raising its full-year outlook.